Rare earths are foundational to many of the world’s most important technologies. Producing them end-to-end in the U.S. was considered impossible by some, until @hoomanrenezhad and Artem Iurkovskyi did it in a year with @solcoatech. @alysaaco discusses their journey.

Make money. Have fun. Live with integrity. Everything else can change. Fund XI. $1.6B total capital for those who know that it will.

Make money. Have fun. Live with integrity. Everything else can change. Fund XI. $1.6B total capital for those who know that it will.

We’re announcing that Forus has raised a $150M Series C at a $3B valuation to build the AI network for medicine. Medicine will remain one of the world’s most important industries until humanity achieves immortality, and we are only at the beginning of a new era in what it can do. GLP-1s are changing obesity and cardiometabolic disease. Gene therapies can treat diseases at their genetic source. New cancer treatments are turning diagnoses that were once fatal into diseases people can live with. AI is enabling us to discover of new drugs even faster. But discovery is only the beginning. It still takes more than a decade and billions of dollars to turn a new molecule into an approved medicine, and once it reaches market, more than a third of patients prescribed specialty treatments never receive their first dose. Forus is creating the AI network to accelerate the entire medicine pipeline, from development and launch through prescription and treatment. We connect the companies creating medicines with the doctors who prescribe them and the patients who need them. Today, Forus supports millions of people across all 50 states and is already used by providers to treat patients in 85% of U.S. residential ZIP codes. 9 of the top 15 global biopharma companies work with us, alongside many fast-growing biotechs. Our goal is to put Forus in every doctor’s office in the country and unlock an order of magnitude more medicine for society. There is a generational opportunity to rethink how new medicine reaches people. Forus is becoming how medicine moves from discovery to treatment in America, and as we scale, we’ll become the most important company in life sciences. Forus is not constrained by capital or customer demand; we are constrained by the talent and capacity of our team. To take on the opportunity in front of us, we need exceptional engineers and operators in New York who want to move fast and help us make something that matters. Come build with us. Our Series C was led by Bain Capital Ventures, with Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel investing alongside them.

We’re announcing that Forus has raised a $150M Series C at a $3B valuation to build the AI network for medicine. Medicine will remain one of the world’s most important industries until humanity achieves immortality, and we are only at the beginning of a new era in what it can do. GLP-1s are changing obesity and cardiometabolic disease. Gene therapies can treat diseases at their genetic source. New cancer treatments are turning diagnoses that were once fatal into diseases people can live with. AI is enabling us to discover of new drugs even faster. But discovery is only the beginning. It still takes more than a decade and billions of dollars to turn a new molecule into an approved medicine, and once it reaches market, more than a third of patients prescribed specialty treatments never receive their first dose. Forus is creating the AI network to accelerate the entire medicine pipeline, from development and launch through prescription and treatment. We connect the companies creating medicines with the doctors who prescribe them and the patients who need them. Today, Forus supports millions of people across all 50 states and is already used by providers to treat patients in 85% of U.S. residential ZIP codes. 9 of the top 15 global biopharma companies work with us, alongside many fast-growing biotechs. Our goal is to put Forus in every doctor’s office in the country and unlock an order of magnitude more medicine for society. There is a generational opportunity to rethink how new medicine reaches people. Forus is becoming how medicine moves from discovery to treatment in America, and as we scale, we’ll become the most important company in life sciences. Forus is not constrained by capital or customer demand; we are constrained by the talent and capacity of our team. To take on the opportunity in front of us, we need exceptional engineers and operators in New York who want to move fast and help us make something that matters. Come build with us. Our Series C was led by Bain Capital Ventures, with Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel investing alongside them.

The 2026 Intelligent Applications 40 is here. Now in its sixth year, the IA40 recognizes the top private companies shaping the future of applied AI, from foundational infrastructure to full-stack intelligent applications. This year's list reflects a market maturing fast: → 450+ companies nominated and voted on by 72 investors across 54 leading firms → $410B raised by this year's 45 winners since founding — more than 25x what the inaugural 2021 class had raised at the same point → 23 repeat winners and 22 new entrants, a 49% turnover rate, down from 68% last year, as some of 2025's breakout companies start to entrench The big pattern this year is how companies are “Harnessing the Value of AI.” As frontier models become more capable and commoditized, the winners are increasingly the companies proving they can turn AI capability into real ROI, whether they're building the application, aggregating the models, or supplying the infrastructure underneath. Databricks remains the only company to appear on every IA40 list since we launched it in 2021. Congratulations to all the 2026 IA40 winners. Your work is defining what's possible in this new era of intelligent applications. Explore all 45 winners and our analysis of the companies, categories, and funding patterns defining this year’s list → ordnl.link/RAFgnA7 Thank you to our great partners: @AWSstartups, @GoogleStartups, @Microsoft, @NYSE, @Delta, and @McKinsey.

Come celebrate our acquisition of Gong cha! Chill bubble tea cafe night with friends like Mintlify, Tomo, Fleet and Cogent. There will be bubble tea. Table space. Maybe a bubble machine?